Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

JR Perry, N Laperriere, CJ O'Callaghan, AA Brandes, J Menten, C Phillips, M Fay, R Nishikawa, JG Cairncross, W Roa, D Osoba, JP Rossiter, A Sahgal, H Hirte, F Laigle-Donadey, E Franceschi, O Chinot, V Golfinopoulos, L Fariselli, A WickL Feuvret, M Back, M Tills, C Winch, BG Baumert, W Wick, K Ding, WP Mason, for the Trial Investigators, Michele Reni

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown. METHODS: We conducted a trial involving patients 65 years of age or older with newly diagnosed glioblastoma. Patients were randomly assigned to receive either radiotherapy alone (40 Gy in 15 fractions) or radiotherapy with concomitant and adjuvant temozolomide. RESULTS: A total of 562 patients underwent randomization, 281 to each group. The median age was 73 years (range, 65 to 90). The median overall survival was longer with radiotherapy plus temozolomide than with radiotherapy alone (9.3 months vs. 7.6 months; hazard ratio for death, 0.67; 95% confidence interval [CI], 0.56 to 0.80; P
Original languageEnglish
Pages (from-to)1027-1037
Number of pages11
JournalNew England Journal of Medicine
Issue number11
Publication statusPublished - 2017


Dive into the research topics of 'Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma'. Together they form a unique fingerprint.

Cite this